Business Context and Reporting Period
This Form 6-K filing by China SXT Pharmaceuticals, Inc. (a British Virgin Islands company) covers the month of December 2022. The report details a financing transaction entered into on December 19, 2022, and closed on December 20, 2022.
Key Financial Metrics
- Financing Proceeds: The Company issued a convertible promissory note for gross proceeds of $1,500,000.
- Note Principal: The original principal amount of the note is $1,595,000.
- Interest Rate: 6% per annum, compounding daily.
- Discount and Fees: The note includes an original issue discount of $95,000 and $20,000 allocated for investor fees and transaction expenses.
- Maturity: Principal and accrued interest are due 12 months after the purchase price delivery date.
- Prepayment Penalty: The Company may prepay the note at 120% of the outstanding balance.
Material Changes
The primary material change reported is the execution of a securities purchase agreement with Streeterville Capital, LLC. This transaction introduces new debt obligations and potential equity dilution through the convertible note structure. The filing does not provide comparative financial data (revenue, profit, or cash flow) for the period.
Guidance, Risks, and Unusual Items
- Redemption Rights: The investor may redeem the note starting six months after the purchase date or upon the effective date of the first prospectus supplement, subject to a maximum monthly redemption of $425,000. Redemption can be in cash or shares, though cash is mandatory if an "Equity Conditions Failure" occurs.
- Conversion Price: If redeemed in shares, the conversion price is the lower of $0.60 or 80% of the average lowest VWAP during the 15 trading days preceding the notice.
- Trigger Events: Upon a "Major Trigger Event," the note balance increases by 15%; for a "Minor Trigger Event," it increases by 5%.
- Default Interest: In the event of default, the interest rate increases to the lesser of 15% per annum or the maximum permitted by law.
- Registration Obligations: The Company must file prospectus supplements to register the shares issuable upon conversion, with at least one filing required by March 24, 2023.
- Trading Restrictions: The investor is restricted from selling more than 15% of the weekly trading volume of the Company's ordinary shares in any given week.
Investor Verification Checklist
- Verify the Company's current cash position to assess its ability to meet potential redemption requests or prepayment penalties.
- Review the definitions of "Trigger Events" and "Equity Conditions Failure" in the attached Exhibits 10.1 and 10.2 to understand dilution risks.
- Confirm the status of the Form F-3 registration statement (File No. 333-252664) and the filing of required prospectus supplements by the March 24, 2023 deadline.
- Assess the impact of the 6% daily compounding interest and potential default rate of 15% on future liquidity.